Novartis washes its hands of a $2.5B Xencor deal, dropping rights to final bispecific program

A centerpiece of Novartis’ $2.5 billion bispecifics deal with Xencor has been sidelined, the California biotech said in its third quarter earnings report Monday, formally ending the agreement in its entirety.

Novartis terminated its ex-US rights to the program dubbed vibecotamab, a bispecific targeting CD123 and CD3 for acute myeloid...

Click to view original post